2-Deoxyglucose: An anticancer and antiviral therapeutic, but not any more a low glucose mimetic

被引:105
|
作者
Kang, HT [1 ]
Hwang, ES [1 ]
机构
[1] Univ Seoul, Dept Life Sci, Seoul 130743, South Korea
关键词
2-deoxyglucose; glucose metabolism; calorie restriction; Sp1; O-GlcNAcylation; transcription;
D O I
10.1016/j.lfs.2005.07.001
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
2-Deoxyglucose (2-DG), a non-metabolizable glucose analogue, blocks glycolysis and inhibits protein glycosylation. It has been tested in multiple studies for possible application as an anticancer or antiviral therapeutic. The inhibitory effect of 2-DG on ATP generation made it a good candidate molecule as a calorie restriction mimetic as well. Furthermore, 2-DG has been utilized in numerous studies to simulate a condition of glucose starvation. Because 2-DG disrupts glucose metabolism, protein glycosylation, and ER quality control at the same time, a cellular or pathologic outcome could be easily misinterpreted without clear understanding of 2-DG's effect on each of these aspects. However, the effect of 2-DG on protein glycosylation has rarely been investigated. A recent study suggested that 2-DG causes hyperGlcNAcylation of proteins, while low glucose supply causes hypoGlcNAcylation. In certain aspects of cellular physiology, this difference could be disregarded, but in others, this may possibly cause totally different outcomes. (c) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1392 / 1399
页数:8
相关论文
共 50 条
  • [31] Caloric Restriction Mimetic 2-Deoxyglucose Antagonizes Doxorubicin-induced Cardiomyocyte Death by Multiple Mechanisms
    Chen, Kai
    Xu, Xianmin
    Kobayashi, Satoru
    Timm, Derek
    Jepperson, Tyler
    Liang, Qiangrong
    JOURNAL OF BIOLOGICAL CHEMISTRY, 2011, 286 (25) : 21993 - 22006
  • [32] Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer
    Yoon, Joon-Kee
    Byeon, Hye Eun
    Ko, Seung Ah
    Park, Bok-Nam
    An, Young-Sil
    Lee, Ho-Young
    Lee, Youn Woo
    Lee, Su Jin
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [33] Cell cycle synchronisation using thiazolidinediones affects cellular glucose metabolism and enhances the therapeutic effect of 2-deoxyglucose in colon cancer
    Joon-Kee Yoon
    Hye Eun Byeon
    Seung Ah Ko
    Bok-Nam Park
    Young-Sil An
    Ho-Young Lee
    Youn Woo Lee
    Su Jin Lee
    Scientific Reports, 10
  • [34] MYOCARDIAL CAPILLARY TRANSPORT AND CELLULAR UPTAKE OF D-GLUCOSE AND L-GLUCOSE, AND 2-DEOXYGLUCOSE
    KUIKKA, J
    LEVIN, M
    TORRESFILHO, IP
    BOUSKELA, E
    GORESKY, CA
    BASSINGTHWAIGHTE, JB
    FEDERATION PROCEEDINGS, 1979, 38 (03) : 1304 - 1304
  • [35] Aldo-keto reductases-mediated cytotoxicity of 2-deoxyglucose: A novel anticancer mechanism
    Zhang, Shi-Qing
    Yung, Kin-Lam Ken
    Chung, Sookja Kim
    Chung, Sum-Man Stephen
    CANCER SCIENCE, 2018, 109 (06) : 1970 - 1980
  • [36] ROLE OF CATECHOLAMINE IN TIME-DEPENDENT HYPERGLYCEMIA DUE TO 2-DEOXYGLUCOSE, MANNITOL, AND GLUCOSE
    YAMAMOTO, H
    NAGAI, K
    NAKAGAWA, H
    BIOMEDICAL RESEARCH-TOKYO, 1983, 4 (05): : 505 - 513
  • [37] STUDIES ON THE RELATIONSHIP BETWEEN CEREBRAL GLUCOSE-TRANSPORT AND PHOSPHORYLATION USING 2-DEOXYGLUCOSE
    HARGREAVES, RJ
    PLANAS, AM
    CREMER, JE
    CUNNINGHAM, VJ
    JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM, 1986, 6 (06): : 708 - 716
  • [38] QUANTITATIVE MEASUREMENT OF LOCAL METABOLIC-RATE FOR GLUCOSE UTILIZING TRITIATED 2-DEOXYGLUCOSE
    ALEXANDER, GM
    SCHWARTZMAN, RJ
    BELL, RD
    YU, J
    RENTHAL, A
    ANNALS OF NEUROLOGY, 1980, 8 (01) : 127 - 127
  • [39] Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia
    Igor Elman
    David Rott
    Alan I. Green
    Daniel D. Langleben
    Scott E. Lukas
    David S. Goldstein
    Alan Breier
    Psychopharmacology, 2004, 176 : 369 - 375
  • [40] Effects of pharmacological doses of 2-deoxyglucose on plasma catecholamines and glucose levels in patients with schizophrenia
    Elman, I
    Rott, D
    Green, AI
    Langleben, DD
    Lukas, SE
    Goldstein, DS
    Breier, A
    PSYCHOPHARMACOLOGY, 2004, 176 (3-4) : 369 - 375